Market Performance - The Shanghai Composite Index experienced a day of sideways trading, closing down 0.09%, while the Shenzhen Component Index and the ChiNext Index fell by 0.85% and 0.91% respectively [1] - Over 3,700 stocks in the Shanghai and Shenzhen markets closed in the red, with total trading volume exceeding 3.28 trillion yuan [1] Sector Movements - The precious metals sector saw significant gains, with stocks like Zhongjin Gold and Western Gold hitting the daily limit [1] - Pharmaceutical stocks collectively strengthened, with companies such as Capstone Bio and Maike Bio also reaching the daily limit [1] - Oil and gas stocks experienced intraday surges, with Zhongman Petroleum hitting the daily limit and China National Offshore Oil Corporation rising over 6% to reach a new high [1] Declines - The commercial aerospace sector faced adjustments, with stocks like China Satellite and China Satcom hitting the daily limit down [1]

Market Overview - The Shanghai Composite Index experienced a slight decline of 0.09% while the Shenzhen Component Index and the ChiNext Index fell by 0.85% and 0.91% respectively [1] - The total market turnover reached 3.28 trillion yuan, with over 1,600 stocks rising [1] Sector Performance - The gold sector showed strong performance, with multiple stocks such as Hunan Gold, Shengda Resources, Sichuan Gold, and China Gold hitting the daily limit [1] - Resource sectors including oil, coal, and gas were active, with stocks like Heshun Petroleum and Intercontinental Oil & Gas also reaching the daily limit [1] - The virus prevention sector saw a surge, with stocks like Maike Biology, Cape Biology, Zhijiang Biology, and Hualan Vaccine hitting the daily limit [1] Declining Sectors - Sectors such as electric motors, automotive parts, semiconductors, communication equipment, satellite internet, robotic actuators, and commercial aerospace experienced declines [1] - The overall market showed a mixed performance with certain sectors like mining, small metals, non-ferrous metals, insurance, fertilizers, securities, and titanium dioxide showing gains [1]

Group 1 - The flu sector experienced a significant surge, with Cap Bio (300639) hitting the daily limit of 20% increase in less than a minute, while other companies like Mike Bio, Jindike, and Oriental Bio rose over 10% [1] - Cap Bio opened at 6.12 and reached a high of 7.25, reflecting a 20.03% increase, with a total market value of 46.87 billion and a circulating market value of 46.05 billion [2][3] - Other notable performers in the flu sector included Hualan Vaccine, which increased by 20%, Mike Bio by 15.22%, and Jindike by 13.62% [3][4] Group 2 - Reports indicated that there are confirmed cases of Nipah virus infection in West Bengal, India, with five cases reported, including healthcare workers, leading to nearly 100 individuals being quarantined [4]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with notable increases such as Kanglaweishi up over 20% and several others reaching the daily limit of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has prompted a response from local authorities, with nearly a hundred individuals under home quarantine due to the high mortality rate of up to 75% and the absence of a vaccine [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal starting January 26 to prevent the virus from entering Thailand [1] Group 2 - Historical context indicates that Nipah virus outbreaks have previously occurred in Malaysia, Singapore, India, Bangladesh, and the Philippines, resulting in significant fatalities and the culling of millions of pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission rate through contaminated food or direct human-to-human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days, and there are currently no specific vaccines or effective treatments available [2] Group 3 - The stock performance of various biopharmaceutical companies shows substantial year-to-date gains, with Kanglaweishi at 45.10%, Maike Biological at 26.90%, and Kaipu Biological at 34.76% [3] - Other companies such as Zhijiang Biological and Jindike also reported significant increases, with year-to-date growth rates of 26.67% and 18.44% respectively [3] - The overall market trend indicates a strong investor interest in biopharmaceutical stocks amid the health crisis related to the Nipah virus outbreak [1][3]

据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 据央视新闻，近期，印度东部的西孟加拉邦出现尼帕病毒感染病例，目前已有5例确诊病例，其中包括 医护人员。据悉，近100人被要求居家隔离，感染者正在该邦首府加尔各答及周边医院接受治疗，其中 一名患者病情危重。 据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最 长可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 1月26日，流感板块午后拉升，截至发稿，迈克生物、凯普生物、之江生物、华兰疫苗20%涨停，达 安基因、特一药业、鲁抗医药、科华生物等涨停，智飞生物、万孚生物、康希诺、沃森生物等涨超 10%。 ...

Group 1 - The core viewpoint of the news is that Capbio (凯普生物) experienced a significant stock price increase, reaching a limit up of 20.03% on January 26, 2026, with a total market capitalization of 4.687 billion yuan [1] - Capbio has recently announced the acquisition of multiple domestic and international patent authorizations, enhancing its technological barriers and core competitiveness [2] - The actual controller, Ms. Wang Jianyu, has completed an increase in holdings amounting to 18.12 million yuan and plans to continue increasing her stake, signaling confidence in the company's development [2] - The company has expanded its business scope by obtaining production qualifications for Class III in vitro diagnostic reagents and Class II obstetric and gynecological instruments [2] - For the first three quarters of 2025, Capbio reported a narrowing of net losses attributable to shareholders by 51.25%, with operating cash flow increasing by 173.06% to 121 million yuan, indicating an improvement in operational conditions [2] - Capbio, as an integrated supplier of molecular diagnostic products and services, is expected to benefit from the growth in the in vitro diagnostics sector within the biopharmaceutical industry [2] - On the market performance side, the biopharmaceutical sector saw active movements, with Capbio's limit-up creating a certain sector linkage effect [2] - Technical indicators such as the MACD forming a golden cross and breaking through the upper Bollinger Band may attract more capital attention [2] - There was likely a flow of main funds into the stock, contributing to the price surge [2]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]

（文章来源：每日经济新闻） 每经AI快讯，1月26日，生物医药概念午后快速拉升，凯普生物直线涨停，沃森生物、圣湘生物、万泽 股份、智飞生物、君实生物跟涨。 ...

流感板块午后再度拉升，凯普生物20cm涨停，智飞生物、万孚生物涨超10%，之江生物、华兰疫苗此 前涨停，康希诺、硕世生物、科华生物涨幅居前。 ...

Group 1 - The company is a leading provider of integrated molecular diagnostic products and services in China [1] - The strategic plan focuses on the collaborative development of three business segments: molecular diagnostic products, medical testing services, and healthcare services [1] - The company has not yet ventured into the brain-computer interface business [1]